Liver Function and Fibrosis Changes in Pediatric CF Patients on LI vs. ETI Therapies
发布者：Unknown
·发布于: 2025-12-13
Discussion regarding the observed longitudinal changes in liver function markers and fibrosis indices in pediatric cystic fibrosis patients treated with Lumacaftor/Ivacaftor (LI) compared to those treated with Elexacaftor/Tezacaftor/Ivacaftor (ETI).